Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Cash from Investing Activities (2016 - 2025)

Conmed (CNMD) has disclosed Cash from Investing Activities for 16 consecutive years, with -$7.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 76.01% year-over-year to -$7.1 million, compared with a TTM value of -$21.0 million through Dec 2025, down 60.17%, and an annual FY2025 reading of -$21.0 million, down 60.17% over the prior year.
  • Cash from Investing Activities was -$7.1 million for Q4 2025 at Conmed, down from -$5.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2.0 million in Q1 2024 and bottomed at -$148.3 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is -$15.9 million, with a median of -$4.6 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities plummeted 9191.67% in 2021, then skyrocketed 96.27% in 2023.
  • Year by year, Cash from Investing Activities stood at -$3.2 million in 2021, then tumbled by 98.18% to -$6.3 million in 2022, then rose by 23.16% to -$4.9 million in 2023, then grew by 16.79% to -$4.0 million in 2024, then crashed by 76.01% to -$7.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for CNMD at -$7.1 million in Q4 2025, -$5.2 million in Q3 2025, and -$5.7 million in Q2 2025.